Similarly, targeting c-MET overexpression (frequency of 13% in glioblastoma) and amplification (5%) with two phase II trials in recurrent glioblastoma, failed to demonstrate improved outcomes [167,168,169]. The gene discussed is MET; the disease is glioblastoma.